구강점막염 치료 시장 : 치료 유형별, 약물 유형별, 유통 채널별, 최종 용도별 - 예측(2024-2032년)

Oral Mucositis Treatment Market size is projected to record 7.1% CAGR from 2024 to 2032, driven by the rising rate of cancer along with the increased demand for effective therapies. Healthcare authorities are reviewing and approving new treatment methods to address the prevalence of oral mucositis among cancer patients undergoing chemotherapy and radiation therapy.

Regulatory agencies are facilitating the approval of innovative therapies for alleviating symptoms and improving the quality of life for cancer patients. Rising research efforts to focus on developing targeted and more efficacious treatment for leveraging advances in medical science and technology will boost the industry growth. For instance, in February 2023, the U.S. FDA granted Priority Review to Avasopasem for treatment-related oral mucositis for recognizing its potential as an advanced therapy in addressing the adverse effects of chemotherapy on oral health in cancer patients.

The overall market is segregated into treatment type, drug class, distribution channel, end-use, and region.

In terms of treatment type, the oral mucositis treatment market from the mouthwash segment is expected to record significant CAGR from 2024 to 2032. Mouthwash helps in soothing and managing symptoms, such as mouth pain and inflammation. Mouthwashes formulated with ingredients like antimicrobials and soothing agents are assisting in providing relief to patients undergoing cancer treatments. Advancements in mouthwash formulations are leading to the integration of novel compounds or targeted delivery systems to enhance efficacy and comfort during treatment.

By distribution channel, the oral mucositis treatment industry size from the online pharmacy segment is projected to rise from 2024 to 2032. Online pharmacies are offering convenience and accessibility for purchasing oral mucositis treatments for providing patients with easy access to medications and supportive care products. These platforms are also enabling patients to browse a variety of treatments including mouthwashes and other oral care products specifically designed to alleviate symptoms of mucositis.

Regionally, the Asia Pacific oral mucositis treatment market size is projected to exhibit robust growth between 2024 and 2032, fueled by the ongoing technological innovations for enhancing the effectiveness and accessibility of treatments for managing oral mucositis. Innovations, such as advanced mouthwash formulations and targeted delivery systems are actively explored to improve symptom relief and patient comfort, adding to the regional industry growth.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of cancer
    • 3.2.1.2 Growing awareness and focus on supportive care
    • 3.2.1.3 Technological advancements in cancer treatment modalities
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 High cost of treatments
    • 3.2.2.2 Limited efficacy of existing treatments
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Porter's analysis
• 3.6 PESTEL analysis
• 3.7 Future market trends

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Treatment Type, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Pain control medication
• 5.3 Mouthwash
• 5.4 Other treatment types

Chapter 6 Market Estimates and Forecast, By Drug Class, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Anti-inflammatory
• 6.3 Antimicrobials
• 6.4 Antifungal
• 6.5 Anti-neoplastic
• 6.6 Antibiotics
• 6.7 Other drug classes

Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Hospital pharmacy
• 7.3 Retail pharmacy
• 7.4 Online pharmacy

Chapter 8 Market Estimates and Forecast, By End-Use, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Hospitals and clinics
• 8.3 Ambulatory surgical centers
• 8.4 Other end-users

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
  • 9.3.7 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
  • 9.4.6 Rest of Asia Pacific
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
  • 9.5.4 Rest of Latin America
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE
  • 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

• 10.1 Amgen Inc.
• 10.2 Basic Pharma Life Science Pvt Ltd.
• 10.3 CANbridge Pharmaceuticals Inc.
• 10.4 Enzychem Lifesciences Corporation
• 10.5 EpicentRx, Inc.
• 10.6 Galera Therapeutics, Inc.
• 10.7 Helsinn Healthcare SA.
• 10.8 Innovation Pharmaceuticals Inc.
• 10.9 Monopar Therapeutics, Inc.
• 10.10 Pfizer Inc.
• 10.11 Soleva Pharma, LLC.
• 10.12 Swedish Orphan Biovitrum AB